Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Commentary|Articles|July 14, 2026
Medicare and Weight-Loss Medications: A Pharmacist's FAQ on the GLP-1 Bridge Program
Author(s)Gillian McGovern, Editor
Fact checked by: Mohammed Chammout, PharmD, BCMTMS , Ron Panarotti
This FAQ breaks down which drugs are covered by the program, who qualifies, how to process claims correctly, and what pharmacists need to know to counsel patients through this landmark shift in obesity drug access.
Advertisement
Advertisement
This FAQ was fact-checked by Mohammed Chammout, PharmD, BCMTMS.
Related to this article
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Advertisement
Advertisement